Acadian Asset Management’s VistaGen Therapeutics VTGN Stock Holding History

Acadian Asset Management’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$178K	Buy	794,579 +204,916	+35%	+$124K	﹤0.01%	1659
2026 Q1	$336K	Buy	+589,663	New	+$358K	﹤0.01%	1454
2024 Q2	–	Sell	-32,291	Closed	-$169K	–	1911
2024 Q1	$169K	Buy	+32,291	New	+$155K	﹤0.01%	1211
2022 Q4	–	Sell	-6,214	Closed	-$28K	–	1929
2022 Q3	$28K	Buy	+6,214	New	+$61.6K	﹤0.01%	1568
2018 Q3	–	Sell	-533	Closed	-$22K	–	1807
2018 Q2	$22K	Buy	+533	New	+$18.5K	﹤0.01%	1518

Other funds holding VTGN

Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return

AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return

Luminus Management Houston, Texas $146M AUM 27.83% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Acadian Asset Management's VTGN Position: Q2 2026 in Review

Acadian Asset Management increased its VistaGen Therapeutics (VTGN) stake by 35% in Q2 2026, buying an estimated $124K and bringing the position to 794,579 shares worth $178K. The position accounts for ﹤0.01% of the portfolio, ranked #1659.

Acadian Asset Management first reported a position in VTGN in Q2 2018 and has held it in 5 quarters since. The position peaked at $336K in Q1 2026. 49 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.

Acadian Asset Management held 794,579 shares of VistaGen Therapeutics worth $178K as of Q2 2026.
Acadian Asset Management bought 204,916 VistaGen Therapeutics shares in Q2 2026, an estimated $124K.
VistaGen Therapeutics made up ﹤0.01% of Acadian Asset Management's portfolio in Q2 2026, its #1659 holding.
Acadian Asset Management first reported a position in VistaGen Therapeutics in Q2 2018 and has held it in 5 quarters since.
Acadian Asset Management's VistaGen Therapeutics position peaked at $336K in Q1 2026.
49 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.

Based on Acadian Asset Management's 13F filing for Q2 2026, filed 13 Aug 2026.